Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

785830

registered interest
date	07/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Suicide: Internet
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the answers by Lord Agnew of Oulton on 7 November and Lord Ashton of Hyde on 6 November (HL Deb, col 1594), what assessment they have made of the presence of sites that promote suicide on the internet, in the light of research published by the University of Manchester in May 2016 which found that 22 per cent of suicide victims had been bullied and 27 per cent of victims had been experiencing academic pressures at school, college or university.
tabling member printed	Lord Alton of Liverpool
uin	HL2978
answer	answer is ministerial correction date of answer 21/11/2017 answer text <p>We are aware of the positive and negative impacts that the internet can have on mental wellbeing and the potential harmful effect of websites with content that promotes suicide. We expect online providers to take action where harmful content is identified or online abuse is reported and breaches their policies. The recently enacted Digital Economy Act will help to ensure that online abuse is effectively tackled by requiring a code of practice to be established, which will set out guidance for social media providers on what they should do in relation to harmful or inappropriate conduct on their platforms. We also support organisations such as the Samaritans, which works with online providers to improve the way that online users can report harmful content and encourages providers to take action.</p><p> </p><p>The Government provided £1.5 million to fund research through the Cross-Government Suicide Prevention Strategy and this included research into the use of the internet by people with experience of suicide. It showed that people with experience of suicide have used the internet to find information and support online as well as searching suicidal content and that we should seek to harness the positive effects of the internet and support vulnerable people online. The Government is consulting on the National Internet Safety Strategy until 7 December, which seeks to improve safety online for everyone.</p><p> </p><p>We welcome the study by the National Confidential Inquiry into Suicide and Homicide by People with Mental Illness on Suicide by Children and Young People in England (May 2016) and we considered its findings when updating the Cross-Government Suicide Prevention Strategy this year.</p> answering member printed Lord O'Shaughnessy question first answered 21/11/2017 13:56:17 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	738 label Biography information for Lord Alton of Liverpool

785831

registered interest
date	07/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Suicide: Internet
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the answers by Lord Agnew of Oulton on 7 November and Lord Ashton of Hyde on 6 November (HL Deb, col 1594), what assessment they have made of a study published in the British Medical Journal in April 2008 which found that websites providing information about suicide were more likely to be encouraging the act of suicide than offering support to potential victims.
tabling member printed	Lord Alton of Liverpool
uin	HL2979
answer	answer is ministerial correction date of answer 21/11/2017 answer text <p>We have made no formal assessment of the 2008 British Medical Journal study.</p><p> </p><p>We are aware of the positive and negative impacts that the internet can have on mental wellbeing and the potential harmful effect of websites with content that promotes suicide. We provided £1.5 million of funding through the Cross-Government Suicide Prevention Strategy for further research on suicide prevention. This included research undertaken by Lucy Biddle for Bristol University, who was involved in the study referenced in 2008. This further research was published last year and showed that people with experience of suicide have used the internet to find information and support online as well as searching suicidal content and that we should seek to harness the positive effects of the internet and support vulnerable people online. A summary of this research, <em>Priorities for suicide prevention: balancing the risks and opportunities of internet use</em>, is attached. We also support organisations such as the Samaritans, which works with online providers to improve the way that online users can report harmful content and encourages providers to take action.</p><p> </p><p>The Government is committed to making the United Kingdom the safest place online and until 7 December is consulting on the National Internet Safety Strategy, which seeks to improve safety online for everyone.</p> answering member printed Lord O'Shaughnessy question first answered 21/11/2017 13:57:47 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name PolicyBristol_Report_7_suicide_and_internet_use.pdf title Suicide prevention
tabling member	738 label Biography information for Lord Alton of Liverpool

785843

registered interest
date	07/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: Children and Young People
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the answer by Lord O'Shaughnessy on 30 October (HL Deb, col 1160), when they anticipate that the Green Paper on children and young people’s mental health will be published; and what plans they have to ensure that that Green Paper assesses differences in mental health treatment resulting from geographical location.
tabling member printed	Lord Brooke of Alverthorpe
uin	HL2991
answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>We plan to publish the Green Paper on children and young people’s mental health by the end of this year.</p><p>The Green Paper will include specific proposals to improve provision and access to mental health services for all children who need them irrespective of geographical location.</p> answering member printed Lord O'Shaughnessy question first answered 20/11/2017 15:59:59 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	3335 label Biography information for Lord Brooke of Alverthorpe

785844

registered interest
date	07/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Psychiatric Hospitals
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government when they will publish their response to the report of the Commission on Adult Inpatient Psychiatric Care.
tabling member printed	Lord Crisp
uin	HL2992
answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>NHS England, working with other arm’s length bodies, has prepared a response to recommendations from the Commission on Adult Psychiatric Care in England. The response will be published in due course.</p><p> </p><p>Inappropriate out-of-area placements are unacceptable and the Government has committed to eliminate these in non-specialist, acute mental health care by 2020/21.</p> answering member printed Lord O'Shaughnessy question first answered 20/11/2017 15:32:59 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	3783 label Biography information for Lord Crisp

785845

registered interest
date	07/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Sclerosis: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking to improve NHS patient access to the latest innovative cost-effective medicines for multiple sclerosis.
tabling member printed	Lord Dubs
uin	HL2993
answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) makes authoritative, evidence-based recommendations for the National Health Service on the clinical and cost effective use of drugs and other treatments. Wherever possible, NICE aims to publish draft guidance on significant new drugs as soon as possible after licensing. NICE has recommended a number of drugs as treatments for multiple sclerosis.</p><p> </p><p>Commissioners are legally required to fund drugs and treatments recommended in NICE technology appraisal guidance within three months of its final guidance being issued. This is reflected in the NHS Constitution as a right to NICE approved drugs.</p> answering member printed Lord O'Shaughnessy question first answered 20/11/2017 12:31:36 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	805 label Biography information for Lord Dubs

785846

registered interest
date	07/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Sclerosis: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of (1) advances in treatments for multiple sclerosis for NHS patients, including the recently approved first short course oral treatment, cladribine tablets; and (2) the extent to which new treatments will help to reduce burdens on NHS services.
tabling member printed	Lord Dubs
uin	HL2994
answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>The Department has made no such assessment.</p><p> </p><p>Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) makes recommendations on whether selected drugs and treatments represent a clinically and cost effective use of National Health Service resources, taking into account the impact on the health service of a product.</p><p> </p><p>NICE is currently developing guidance on the use of cladribine for treating multiple sclerosis and expects to publish final guidance in December.</p> answering member printed Lord O'Shaughnessy question first answered 20/11/2017 12:32:32 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	805 label Biography information for Lord Dubs

785876

registered interest
date	07/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Psychiatry: Vacancies
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, in the light of the Royal College of Psychiatrists workforce census 2017, which reported a rise in the number of vacant or unfilled psychiatrist consultant posts across the UK to 9 per cent, what steps they are taking to address that rise and to ensure that patient waiting times do not increase.
tabling member printed	The Marquess of Lothian
uin	HL3024
answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>We want people with mental health conditions to receive better treatment, and part of that means having the right National Health Service staff. We know we need to do much more to attract, retain and support the mental health workforce of the future, which is why we launched a plan to do just that in July.</p><p> </p><p>In <em>Stepping forward to 2020/21: A mental health workforce plan for England</em>, Health Education England sets out a plan to transform the mental health workforce, including a number of key actions to increase workforce supply. A copy is attached. Current initiatives to improve recruitment into psychiatry training posts include increasing the number of training placements in psychiatry in the Foundation Programme and supporting the Royal College of Psychiatrists on its marketing campaign ‘Choose Psychiatry’.</p><p><strong> </strong></p><p>On 4 October 2016, my Rt. hon. Friend, the Secretary of State announced the expansion of undergraduate medical education by up to 1,500 new medical school places in each year, with 500 additional places available in September 2018. The criteria for allocating the remaining 1,000 places from September 2019 includes alignment to local NHS workforce needs, with an emphasis on priority specialties such as psychiatry and priority areas, including rural and coastal areas.</p> answering member printed Lord O'Shaughnessy question first answered 20/11/2017 15:59:05 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name Stepping forward to 2020 The mental health workforce plan for England July 2017.pdf title Mental health workforce plan
tabling member	259 label Biography information for The Marquess of Lothian

785879

registered interest
date	07/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Side Effects
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 2 November (HL2355), what are the internationally understood definitions of (1) "suspected adverse event", and (2)"‘serious adverse event", following the administration of a drug.
tabling member printed	The Countess of Mar
uin	HL3027
answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>My previous answer of 2 November referred specifically to reports from clinical trials. In the context of clinical trials, an adverse event (AE) is defined as: ‘Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.’ A serious adverse event (SAE) is defined as: ‘Any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect’.</p><p> </p><p>The term ‘suspected’ is not used in the context of AEs and SAEs.</p><p> </p><p>The definition of an adverse drug reaction (ADR) is a response to a medicinal product which is noxious and unintended. Through the Yellow Card Scheme, the Medicines and Healthcare products Regulatory Agency encourages anyone to report a suspected ADR. For suspected ADRs, there is not necessarily a causal relationship with the medicine, but a suspicion by the reporter that the medicine may have been responsible. Suspected ADRs are continuously reviewed to detect possible new risks.</p> answering member printed Lord O'Shaughnessy question first answered 20/11/2017 12:23:22 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar

785880

registered interest
date	07/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 2 November (HL2355), what are the latest figures for (1) suspected adverse events, and (2) serious adverse events, relating to (a) Gardasil, and (b) Cevarix, since those vaccines were introduced; and how many of those who reported serious adverse events remain incapacitated.
tabling member printed	The Countess of Mar
uin	HL3028
answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>Through the Yellow Card Scheme, the Medicines and Healthcare products Regulatory Agency (MHRA) has received 9,007 reports of suspected adverse reactions (ADRs) to human papillomavirus (HPV) vaccine, up to the 6 November 2017. This follows administration of more than nine million doses of HPV vaccine in the United Kingdom. A breakdown by brand and severity is provided in the table below.</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Total</p></td><td><p>Serious</p></td></tr><tr><td><p>HPV brand unspecified</p></td><td><p>691</p></td><td><p>485</p></td></tr><tr><td><p>Cervarix</p></td><td><p>6,323</p></td><td><p>1,822</p></td></tr><tr><td><p>Gardasil</p></td><td><p>1,961</p></td><td><p>842</p></td></tr><tr><td><p>Gardasil 9</p></td><td><p>37</p></td><td><p>18</p></td></tr><tr><td><p>Total</p></td><td><p>9,007</p></td><td><p>3,162</p></td></tr></tbody></table><p><em>Source</em>: MHRA Sentinel database for ADRs.</p><p>It should be noted that the total number of reports received by vaccine brand is not equal to the totals in the table above, as some reports included more than one HPV vaccine brand.</p><p> </p><p>Each report may contain more than one symptom. Of the serious reports, 25% include a symptom that is recorded as not recovered. This is based on the information available on outcome at the time of reporting and cannot be used to determine the number of patients with persistent symptoms. While the MHRA encourages reporters to update the outcome, this is not always provided.</p><p> </p> answering member printed Lord O'Shaughnessy question first answered 20/11/2017 12:30:55 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar

785885

registered interest
date	07/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking to address the financial cost to society of (1) alcohol misuse, (2) obesity, and (3) viral hepatitis.
tabling member printed	Baroness Randerson
uin	HL3033
answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>The Government wants everyone to be able to make healthier choices, regardless of their circumstances, and to minimise the risk and impact of illness. A range of action is being taken to do this, in particular across the three areas identified.</p><p> </p><p>To tackle alcohol misuse we are preventing below cost selling, tightening the rules on irresponsible promotions and introducing new powers to deal with anti-social behaviour. Local authorities are supported by Public Health England (PHE) in the commissioning of high quality, evidence based treatment services for their local populations’ needs.</p><p> </p><p>In addition, the United Kingdom Chief Medical Officers have produced new low risk drinking guidelines which provide the public with the latest information about the health risks of different levels and patterns of drinking. The guidelines enable people to make informed choices about their drinking.</p><p> </p><p>Tackling childhood obesity is a priority for this Government. We launched <em>Childhood Obesity: A Plan for Action</em> in August 2016. Our world-leading plan will help children and families to recognise and make healthier choices and be more active. Many of the key commitments in our plan will have an impact on tackling obesity across all age groups. These include the soft drinks industry levy and sugar reduction programme, which will reduce the amount of sugar we all consume. A copy of <em>Childhood Obesity: A Plan for Action</em> is attached.</p><p> </p><p>The National Strategic Group on Viral Hepatitis is a PHE-supported, cross-agency expert group on viral hepatitis with external membership from academia, NHS England, local government, clinical commissioning groups, patient representative groups and other organisations, to provide strategic direction and advice around viral hepatitis. The strategy group aims to help reduce the incidence, prevalence and consequences of infection from the viral hepatitides in England.</p><p> </p><p><strong> </strong></p> answering member printed Lord O'Shaughnessy question first answered 20/11/2017 12:25:14 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name Childhood obesity -A Plan for Action.pdf title Childhood obesity plan
tabling member	4230 label Biography information for Baroness Randerson